Submit Manuscript  

Article Details


Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer

[ Vol. 22 , Issue. 13 ]

Author(s):

Phool Chandra*, Neetu Sachan and Dilipkumar Pal   Pages 1548 - 1554 ( 7 )

Abstract:


A serine/threonine-protein kinase, recognized as Glycogen Synthase Kinase-3 (GSK-3), is documented as a regulator of assorted cellular roles. GSK-3 activates by phosphorylation and thereby controls the action of many physiological, messenger, and membrane-bound structures. GSK-3α and GSK-3β are two vastly homologous forms of GSK-3 in mammals. Recent information has recommended that GSK-3β is a constructive controller of cancer cell proliferation and a promising key target against cancer cells. GSK-3 is overexpressed in various tumor types, including ovarian tumors. In human breast carcinoma, it has been revealed that the overexpression of GSK-3β was linked with breast cancer patients. The inhibition of GSK-3 or inhibitors of GSK-3 is a promising therapeutic tactic to overcome breast and ovarian cancer. This article features an important aspect of inhibitors of Glycogen Synthase Kinase-3 as a new lead for treating breast and ovarian Cancer.

Keywords:

Glycogen synthase kinase-3, breast cancer, ovarian cancer, tumor, cell cycle, proliferation.

Affiliation:

Department of Physiology & Pharmacology, School of Pharmaceutical Sciences, IFTM University, Lodhipur Rajput, Delhi Road (NH-24), Moradabad-244 102 (U.P.), Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, IFTM University, Lodhipur Rajput, Delhi Road (NH-24), Moradabad-244 102 (U.P.), Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur-495009, Chhattisgarh

Graphical Abstract:



Read Full-Text article